Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid (Cyto-PB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02883894|
Recruitment Status : Completed
First Posted : August 30, 2016
Last Update Posted : August 30, 2016
Bullous pemphigoid is the most common subepidermal autoimmune blistering disease of the skin in European countries, including France.
Immunologically, BP is characterized by the production of autoantibodies directed against two major components of the hemidesmosome, BP180 and BP230.
The anti-BP180 autoantibody is detected in 79-93% of cases of bullous pemphigoid and its serum level at diagnosis have been correlated with disease activity. The anti-BP230 autoantibody is detected in 57%-63% of bullous pemphigoid cases and its score at diagnosis did not correlate with disease activity.
Up to now, no clinical or immunologic factors have been identified to predict outcome of patients with good or poor prognosis bullous pemphigoid as defined by long complete remission off therapy and recurrent disease requiring maintenance therapy for years. The usefulness of BP180 or BP230 ELISA scores for monitoring BP patients during treatment also remains unclear.
|Condition or disease||Intervention/treatment|
|Bullous Pemphigoid||Other: Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
Aim of the study were :
To study association between the serum level of cytokines (IL-17 and IL-23) and of the protease MMP-9 and the relapse of bullous pemphigoid.
|Study Type :||Observational|
|Actual Enrollment :||120 participants|
|Official Title:||Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid|
|Study Start Date :||November 2009|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||April 2014|
Patients with bullous pemphigoid.
Other: Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9
- Relapse of bullous pemphigoid. [ Time Frame: Month 12 ]The relapse of bullous pemphigoid is defined as he reappearance of at least 3 new daily blisters along with pruritus and/or erythematous, eczematous or urticarial plaques
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02883894
|Chu de Reims|
|Reims, France, 51092|